Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi

被引:400
作者
Kublin, JG
Cortese, JF
Njuniu, EM
Mukadam, RAG
Wirima, JJ
Kazembe, PN
Djimdé, AA
Kouriba, B
Taylor, TE
Plowe, CV
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, Baltimore, MD 21201 USA
[2] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA
[3] Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi
[4] Lilongwe Cent Hosp, Lilongwe, Malawi
[5] Trop Dis Res Ctr, Ndola, Zambia
[6] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali
关键词
D O I
10.1086/375419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 1993, Malawi became the first African country to replace chloroquine with sulfadoxine-pyrimethamine nationwide in response to high rates of chloroquine-resistant falciparum malaria. To determine whether withdrawal of chloroquine can lead to the reemergence of chloroquine sensitivity, the prevalence of the pfcrt 76T molecular marker for chloroquine-resistant Plasmodium falciparum malaria was retrospectively measured in Blantyre, Malawi. The prevalence of the chloroquine-resistant pfcrt genotype decreased from 85% in 1992 to 13% in 2000. In 2001, chloroquine cleared 100% of 63 asymptomatic P. falciparum infections, no isolates were resistant to chloroquine in vitro, and no infections with the chloroquine-resistant pfcrt genotype were detected. A concerted national effort to withdraw chloroquine from use has been followed by a return of chloroquine-sensitive falciparum malaria in Malawi. The reintroduction of chloroquine, ideally in combination with another antimalarial drug, should be considered in areas where chloroquine resistance has declined and safe and affordable alternatives remain unavailable.
引用
收藏
页码:1870 / 1875
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1996, WHOMAL961077
[2]   Chloroquine- and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo -: a pilot study in rural Zambia [J].
Bijl, HM ;
Kager, J ;
Koetsier, DW ;
van der Werf, TS .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2000, 5 (10) :692-695
[3]   BEYOND CHLOROQUINE - IMPLICATIONS OF DRUG-RESISTANCE FOR EVALUATING MALARIA THERAPY EFFICACY AND TREATMENT POLICY IN AFRICA [J].
BLOLAND, PB ;
LACKRITZ, EM ;
KAZEMBE, PN ;
WERE, JBO ;
STEKETEE, R ;
CAMPBELL, CC .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :932-937
[4]   AFRICAN SERUM INTERFERENCE IN THE DETERMINATION OF CHLOROQUINE SENSITIVITY IN PLASMODIUM-FALCIPARUM [J].
CARLIN, JM ;
VANDEWAA, JA ;
JENSEN, JB ;
AKOOD, MAS .
ZEITSCHRIFT FUR PARASITENKUNDE-PARASITOLOGY RESEARCH, 1984, 70 (05) :589-597
[5]   High recombination rate in natural populations of Plasmodium falciparum [J].
Conway, DJ ;
Roper, C ;
Oduola, AMJ ;
Arnot, DE ;
Kremsner, PG ;
Grobusch, MP ;
Curtis, CF ;
Greenwood, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4506-4511
[6]   Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America [J].
Cortese, JF ;
Caraballo, A ;
Contreras, CE ;
Plowe, CV .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (07) :999-1006
[7]  
Djimdé A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
[8]   Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria [J].
Djimdé, A ;
Doumbo, OK ;
Steketee, RW ;
Plowe, CV .
LANCET, 2001, 358 (9285) :890-891
[9]   Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine [J].
Duraisingh, MT ;
Drakeley, CJ ;
Muller, O ;
Bailey, R ;
Snounou, G ;
Targett, GAT ;
Greenwood, BM ;
Warhurst, DC .
PARASITOLOGY, 1997, 114 :205-211
[10]   Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum [J].
Durand, R ;
Jafari, S ;
Vauzelle, J ;
Delabre, JF ;
Jesic, Z ;
Le Bras, J .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2001, 114 (01) :95-102